Personalis (NASDAQ:PSNL) has received an average broker rating score of 1.88 (Buy) from the four analysts that cover the company, Zacks Investment Research reports. Two research analysts have rated the stock with a hold recommendation and two have assigned a strong buy recommendation to the company.
Brokers have set a 12-month consensus price target of $28.00 for the company and are predicting that the company will post ($0.31) earnings per share for the current quarter, according to Zacks. Zacks has also given Personalis an industry rank of 68 out of 256 based on the ratings given to related companies.
A number of equities research analysts have recently issued reports on the stock. CIBC reissued a “hold” rating on shares of Sandstorm Gold in a research note on Monday, July 15th. Oppenheimer set a $110.00 price target on shares of Medtronic and gave the company a “buy” rating in a research note on Monday, July 15th. Bank of America set a $68.00 price target on shares of Inphi and gave the company a “buy” rating in a research note on Monday, July 15th. Cowen reissued a “buy” rating on shares of Avrobio in a research note on Monday, July 15th. Finally, Morgan Stanley set a $70.00 price target on shares of Edison International and gave the company a “hold” rating in a research note on Monday, July 15th.
Shares of Personalis stock traded down $0.55 on Tuesday, reaching $22.04. The company had a trading volume of 141,500 shares, compared to its average volume of 548,827. Personalis has a 52-week low of $20.21 and a 52-week high of $31.88.
In other Personalis news, Director Ken Ludlum acquired 70,000 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $1,190,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Personalis Company Profile
Personalis, Inc operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and diagnostics.
Featured Story: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Personalis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Personalis and related companies with MarketBeat.com's FREE daily email newsletter.